{"contentid": 488609, "importid": NaN, "name": "Diurnal expands deal with Citrine Medicine for Efmody", "introduction": "UK endocrine diseases specialist Diurnal Group has extended its exclusive license agreement with the specialty pharma company, Citrine Medicine, to include the registration, distribution and marketing of Efmody (hydrocortisone modified-release hard capsules \u00e2\u0080\u0093 previously named Chronocort) covering China, Hong Kong, Taiwan and Macau.", "content": "<p>UK endocrine diseases specialist Diurnal Group (AIM: DNL) has extended its exclusive license agreement with the specialty pharma company, Citrine Medicine, to include the registration, distribution and marketing of Efmody (hydrocortisone modified-release hard capsules &ndash; previously named Chronocort) covering China, Hong Kong, Taiwan and Macau.</p>\n<p>News of the deal sent Diurnal&rsquo;s shares up as much as 5% to 72 pence in early London trading this morning.</p>\n<p>Under the terms of the accord, Diurnal will receive a non-refundable upfront payment of $1.0 million and $28.75 million in additional cash payments on the achievement of certain regulatory milestones and sales milestones based on annual sales thresholds. Diurnal will also receive tiered royalties on sales ranging from low to mid double-digits.</p>\n<p>Citrine is a therapeutics platform company focused on the Greater China market that was co-founded by Vivo Capital, F-Prime Capital and Eight Roads Ventures. Citrine is focused on creating a therapeutic platform to deliver rare disease drugs to the Chinese market and to develop the first ever rare disease ecosystem in the country.</p>\n<h2><strong>Adds to Alkindi deal</strong></h2>\n<p>The company signed an original licensing <a href=\"https://www.thepharmaletter.com/in-brief/brief-diurnal-partners-in-china-for-alkindi\">agreement with Citrine in January</a> 2021 for obtaining registration for Alkindi (hydrocortisone granules in capsules for opening) as well as for all commercialization activities in China.</p>\n<p>Citrine will be responsible for obtaining registration for Efmody as treatment of patients with the rare conditions congenital adrenal hyperplasia (CAH) and adrenal insufficiency (AI) in China and for all commercialization activities, including pricing and reimbursement.</p>\n<p>Citrine will initially utilize product from Diurnal&rsquo;s European supply chain, with an option to establish its own supply chain in China in the future. It is estimated that CAH occurs in one in 6,084 births in China. CAH is a group of genetic conditions that limit hormone production in the adrenal glands and was identified a rare disease by the Chinese health authorities in May 2018.</p>", "date": "2021-05-12 14:35:00", "meta_title": "Diurnal expands deal with Citrine Medicine for Efmody", "meta_keywords": "Diurnal, Citrine Medicine, Efmody, License, Agreement, Registration, Hyperplasia, Adrenal, CAH", "meta_description": "Diurnal expands deal with Citrine Medicine for Efmody", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-12 14:33:01", "updated": "2021-05-12 14:42:48", "access": NaN, "url": "https://www.thepharmaletter.com/article/diurnal-expands-deal-with-citrine-medicine-for-efmody", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "diurnal_logo-_big.jpg", "image2id": "diurnal_logo_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Endocrinology, Rare diseases", "topic_tag": "Asia Pacific, Deals, Focus On, Licensing, Regulation", "geography_tag": "China, Taiwan, UK", "company_tag": "Citrine Medicine, Diurnal Group", "drug_tag": "Alkindi, Chronocort, Efmody", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-12 14:35:00"}